P141: Persistent Growth-Promoting Effects of Vosoritide in Children with Achondroplasia is Accompanied by Improvement in Physical Aspects of Quality of Life*
Genetics in Medicine Open(2024)
Abstract
Vosoritide, a potent stimulator of endochondral bone growth, is approved for use in children with achondroplasia (ACH) until closure of epiphyses. A 52-week, phase 3, pivotal trial (111-301) demonstrated a significant improvement in annualized growth velocity (AGV) with vosoritide compared to placebo in children with ACH aged 5-18 years. We report data from Quality of Life in Short Stature Youth (QoLISSY) questionnaires collected for treated children in study 111-301 and its ongoing open-label extension study 111-302.
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined